At the news
? BULLISHIMPACT 7/10 8-K filed May 13, 2026 at 16:22 ET
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consensus of -$0.57 (actual -$0.58). More importantly, the company announced a manufacturing divestiture and ZYNYZ royalty monetization expected to provide up to $202.5M in non-dilutive capital, extending cash runway through 2028 and reducing near-term financing risk.
- Revenue grew 57% YoY to $20.8M driven by contract manufacturing and royalty revenue
- Net loss narrowed to $36.8M from $41.0M in Q1 2025
- EPS of -$0.58 vs consensus -$0.57 (in line)
- Manufacturing operations divestiture to Bora Pharmaceuticals for $122.5M upfront
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access